© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Joseph F. Renzulli, II, MD, FACS, assistant professor of Surgery, (Urology), Alpert Medical School, Brown University, discusses a phase II study that examined the use of abiraterone acetate with low-dose prednisone in patients with prostate cancer.